{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:55:50Z","timestamp":1793973350387,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jhep.2022.06.018","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T21:42:45Z","timestamp":1656538965000},"page":"1399-1409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH"],"prefix":"10.1016","volume":"77","author":[{"given":"Nikolai V.","family":"Naoumov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Brees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-2024","authenticated-orcid":false,"given":"Patricia","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lamle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2022.06.018_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib3","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry","year":"2018"},{"key":"10.1016\/j.jhep.2022.06.018_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.06.018_bib5","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.06.018_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.06.018_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Friedman SL Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep4.1055","article-title":"Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation","volume":"1","author":"Brunt","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.06.018_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2022.06.018_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.06.018_bib13","series-title":"Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH)","year":"2018"},{"key":"10.1016\/j.jhep.2022.06.018_bib14","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib15","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.06.018_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steato-sis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gut.2005.084475","article-title":"An appraisal of the histopathological assessment of liver fibrosis","volume":"55","author":"Standish","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.06.018_bib18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/apt.15503","article-title":"Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials","volume":"50","author":"Pai","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.06.018_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anndiagpath.2010.08.001","article-title":"Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology","volume":"15","author":"Gawrieh","year":"2011","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jhep.2022.06.018_bib20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2022.06.018_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2022.06.018_bib22","doi-asserted-by":"crossref","DOI":"10.1117\/1.3041159","article-title":"Nonlinear optical microscopy: use of second harmonic generation and two-photon microscopy for automated quantitative liver fibrosis studies","volume":"13","author":"Sun","year":"2008","journal-title":"J\u00a0Biomed Opt"},{"key":"10.1016\/j.jhep.2022.06.018_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2009.12.009","article-title":"Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis","volume":"52","author":"Gailhouste","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","article-title":"qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients","volume":"61","author":"Xu","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcp\/aqx104","article-title":"Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease","volume":"148","author":"Liu","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jhep.2022.06.018_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199166","article-title":"Second harmonic generation microscopy provides accurate auto-mated staging of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.06.018_bib27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/hep.30986","article-title":"qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.06.018_bib28","first-page":"101A","article-title":"Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGT-FXR study","volume":"72","author":"Lucas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib29","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jhep.2022.06.018_bib30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.06.018_bib31","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.21595","article-title":"Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis","volume":"45","author":"Goodman","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib32","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2022.06.018_bib33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"The complexity of ballooned hepatocyte feature recognition: defining a training atlas for imaging-based artificial intelligence in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib34","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/hep.29009","article-title":"New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment","volume":"65","author":"Sun","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/hep.29111","article-title":"On beyond staging and grading: liver biopsy evaluation in a posttreatment world","volume":"65","author":"Kleiner","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib36","series-title":"AASLD","article-title":"Steatosis and fibrosis measured as continuous variables on paired, serial liver biopsies in the resmetirom (MGL-3196) 36-week phase 2 NASH study","author":"Harrison","year":"2019"},{"key":"10.1016\/j.jhep.2022.06.018_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.28860","article-title":"Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood","volume":"65","author":"Decaris","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.06.018_bib39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib40","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41598-018-21179-2","article-title":"Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak \u2018stable\u2019 patients on anti-HBV therapy","volume":"8","author":"Sun","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.06.018_bib41","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/gutjnl-2019-318841","article-title":"Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.06.018_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3350\/cmh.2020.0181","article-title":"Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: histological perspective","volume":"27","author":"Soon","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib43","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.cgh.2019.12.025","article-title":"High-throughput, machine learning-based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease","volume":"18","author":"Forlano","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151518","article-title":"Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD","volume":"47","author":"Gawrieh","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.jhep.2022.06.018_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41374-019-0315-9","article-title":"Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD\/NASH","volume":"100","author":"De Rudder","year":"2020","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhep.2022.06.018_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154707","article-title":"Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters","volume":"117","author":"Briand","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2022.06.018_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.31750","article-title":"A\u00a0machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH","volume":"74","author":"Taylor-Weiner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib49","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jhep.2018.03.023","article-title":"Digital pathology, what is the future?","volume":"70","author":"Paradis","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.018_bib50","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/hep.31207","article-title":"Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides","volume":"72","author":"Saillard","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.06.018_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinre.2019.07.009","article-title":"Quantitative SHG-microscopy: unraveling the nano-architecture of the cirrhotic liver","volume":"44","author":"Wanless","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2022.06.018_bib52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jclinpath-2020-206764","article-title":"Diagnostic concordance and discordance in digital pathology: a systematic review and meta-analysis","volume":"74","author":"Azam","year":"2021","journal-title":"J\u00a0Clin Pathol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:55Z","timestamp":1759175275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0168827822004123"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742220065.793594614","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}